A phase 1/2 dose escalation study of TRU-015 in subjects with relapsed or refractory B cell non-Hodgkin's lymphoma
Latest Information Update: 10 Nov 2021
At a glance
- Drugs TRU 015 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Wyeth
- 04 Apr 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 27 Dec 2007 Status changed from initiated to recruiting.
- 03 Sep 2007 New trial record.